Increasing oxime efficacy by blood-brain barrier modulation

Toxicology Letters

Volumn 206, Issue 1, 2011, Pages 67-71

  Joosen, Marloes J A ^a   van der Schans, Marcel J ^a   van Dijk, Christian G M ^a   Kuijpers, Willem C ^a   Wortelboer, Heleen M ^a   van Helden, Herman P M ^a  

^a TNO   (Netherlands)

Author keywords

HI6; Nerve agent; P glycoprotein; Seizures; Tariquidar

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; ACETYLCHOLINESTERASE; ATROPINE; TARIQUIDAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD LEVEL; BRAIN BLOOD VOLUME; CONTROLLED STUDY; CONVULSION; DRUG EFFECT; DRUG EFFICACY; DRUG INTOXICATION; DRUG PENETRATION; MALE; MICRODIALYSIS; MODULATION; NERVE AGENT POISONING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SEIZURE;

ANIMALS; ANTIDOTES; BLOOD-BRAIN BARRIER; BRAIN; CHEMICAL WARFARE AGENTS; CHOLINESTERASE INHIBITORS; CHOLINESTERASES; ELECTROPHORESIS, CAPILLARY; MALE; MICRODIALYSIS; OXIMES; P-GLYCOPROTEIN; PYRIDINIUM COMPOUNDS; QUINOLINES; RATS; RATS, WISTAR; SEIZURES; SOMAN;

RATTUS;

EID: 80051808751     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.05.231     Document Type: Article

References (25)

1. Brandt C., Bethmann K., Gastens A.M., Loscher W. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol. Dis. 2006, 1:202-211.
2. Bueters T.J., Joosen M.J., van Helden H.P., Ijzerman A.P., Danhof M. Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin. J. Pharmacol. Exp. Ther. 2003, 3:1307-1313.
3. Cook A.M., Whitlow J., Hatton J., Young B. Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use. Expert Opin. Drug Safe. 2009, 4:411-419.
4. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 88-95.
5. Fox E., Bates S.E. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 2007, 4:447-459.
6. Harrison P.K., Sheridan R.D., Green A.C., Tattersall J.E. Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus. Eur. J. Pharmacol. 2005, 2-3:123-132.
7. Hatton J., Rosbolt B., Empey P., Kryscio R., Young B. Dosing and safety of cyclosporine in patients with severe brain injury. J. Neurosurg. 2008, 4:699-707.
8. Hubensack M., Muller C., Hocherl P., Fellner S., Spruss T., Bernhardt G., Buschauer A. Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J. Cancer Res. Clin. Oncol. 2008, 5:597-607.
9. Joosen M.J., Jousma E., van den Boom T.M., Kuijpers W.C., Smit A.B., Lucassen P.J., van Helden H.P. Long-term cognitive deficits accompanied by reduced neurogenesis after soman poisoning. Neurotoxicology 2009, 1:72-80.
10. Lecoeur S., Videmann B., Mazallon M. Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein. Toxicol. Lett. 2006, 3:200-209.
11. Lima S.A., Tavares J., Gameiro P., de Castro B., Cordeiro-da-Silva A. Flurazepam inhibits the P-glycoprotein transport function: an insight to revert multidrug-resistance phenotype. Eur. J. Pharmacol. 2008, 1-2:30-36.
12. Litman T., Skovsgaard T., Stein W.D. Pumping of drugs by P-glycoprotein: a two-step process?. J. Pharmacol. Exp. Ther. 2003, 3:846-853.
13. Luna-Tortos C., Fedrowitz M., Loscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 8:1364-1375.
14. Mazzeo A.T., Beat A., Singh A., Bullock M.R. The role of mitochondrial transition pore, and its modulation, in traumatic brain injury and delayed neurodegeneration after TBI. Exp. Neurol. 2009, 2:363-370.
15. McDonough J.H., Shih T.M. Pharmacological modulation of soman-induced seizures. Neurosci. Biobehav. Rev. 1993, 2:203-215.
16. Mistry P., Stewart A.J., Dangerfield W., Okiji S., Liddle C., Bootle D., Plumb J.A., Templeton D., Charlton P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res. 2001, 2:749-758.
17. Shih T., Whalley C.E., Valdes J.J. A comparison of cholinergic effects of HI-6 and pralidoxime-2-chloride (2-PAM) in soman poisoning. Toxicol. Lett. 1991, 2:131-147.
18. Shih T.M., Duniho S.M., McDonough J.H. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol. Appl. Pharmacol. 2003, 2:69-80.
19. Shih T.M., McDonough J.H. Neurochemical mechanisms in soman-induced seizures. J. Appl. Toxicol. 1997, 4:255-264.
20. Shih T.M., Skovira J.W., O'Donnell J.C., McDonough J.H. In vivo reactivation by oximes of inhibited blood, brain and peripheral tissue cholinesterase activity following exposure to nerve agents in guinea pigs. Chem. Biol. Interact. 2010, 1-3:207-214.
21. Skovira J.W., O'Donnell J.C., Koplovitz I., Kan R.K., McDonough J.H., Shih T.M. Reactivation of brain acetylcholinesterase by monoisonitrosoacetone increases the therapeutic efficacy against nerve agents in guinea pigs. Chem. Biol. Interact. 2010, 1-3:318-324.
22. Stewart A., Steiner J., Mellows G., Laguda B., Norris D., Bevan P. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin. Cancer Res. 2000, 11:4186-4191.
23. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 2:159-165.
24. van Vliet E.A., van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Wadman W.J., Marchi N., Vezzani A., Gorter J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 4:672-680.
25. Worek F., Eyer P., Aurbek N., Szinicz L., Thiermann H. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol. Appl. Pharmacol. 2007, 2-3:226-234.